A new drug class that offers cardioprotective properties are sodium-glucose co-transporter-2 (SGLT-2) inhibitors, initially used for the treatment of type 2 diabetes. Shortly after their introduction into the market they have been shown to have cardioprotective properties that are beyond the effect of lowering the glucose concentration in the blood. After further investigations, their application in non-diabetic patients suffering from heart diseases has been approved. The underlying mechanisms of the observed effects, however, have not yet been identified. The aim of the project is to identify the off-targets of SGLT-2 inhibitors by means of thermal profiling. To get a general impression of the influence of Cana-, Dapa- and Empagliflozin on cardiomyocytes, a differentiated human cardiomyocyte cell line (AC16) has been treated with the three Gliflozins in two different concentrations, being the physiological ones and 100 times higher one.